Not bad
$Intelligent Bio Solutions(INBS.US$ Press Release: Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Dow Jones· 2 mins ago
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
Cash and cash equivalents as of March 31, 2024, was $9.40 million
Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025
Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees
Dow Jones· 2 mins ago
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
Cash and cash equivalents as of March 31, 2024, was $9.40 million
Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025
Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
